Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

atients received two cycles of XL184 administered as a daily oral dose for 5 consecutive days with a 9-day observation period (0.08-11.52 mg/kg), or dosed daily (175 and 265 mg). Patients may remain on study in the absence of unacceptable toxicity or progressive disease. Primary endpoints of the trial are to evaluate the safety and tolerability of XL184, determine the MTD of XL184, and to evaluate the plasma pharmacokinetics of XL184 administered orally to patients with advanced malignancies. Secondary endpoints are to assess the preliminary anti-tumor activity after repeat administration of XL184, and to assess the effects of XL184 on vascular permeability in patients enrolled at the MTD. An evaluation of the pharmacodynamic effects of XL184 is being conducted as an exploratory endpoint.

About XL184

XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models has demonstrated potent inhibition of both MET and VEGFR2. XL184 has also exhibited potent inhibition of other important receptor tyrosine kinases (RTKs) that have been implicated in various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical efficacy studies, XL184 has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma. In laboratory studies, XL184 has demonstrated good oral bioavailability and pharmacokinetic properties.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and ren
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... LA JOLLA, Calif., Feb. 1, 2011 Transdel ... ), a specialty pharmaceutical company focused on developing ... today announced that the Company has been exploring strategic ... banks, American MedTech Advisors and ESC Advisors, a ...
... Feb. 1, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also ... two years, we have progressed the GALNS program from ...
Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA 2BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA 3BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA 4
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... HOUSTON (July 10, 2014) Obese and ... from their health care providers, according to new ... Center at Houston (UTHealth). , National guidelines state ... on the importance of maintaining a healthy weight. ... events are the leading cause of line-of-duty deaths ...
(Date:7/11/2014)... (HealthDay News) -- Prostate cancer patients are more likely ... treatment and die sooner if they also have depression, ... more than 41,200 American men who were diagnosed with ... them through 2009. Nearly 1,900 of the patients had ... their prostate cancer was discovered. "Men with intermediate- ...
(Date:7/11/2014)... Europe is one of the largest ... hence, irrigated land area. The agricultural sector is a ... around 30.0% of the total water use. The scale ... southern region, but far from negligible in most northern ... over 60.0% of the water use in most countries, ...
(Date:7/11/2014)... a history of hazardous or binge drinking reduced their ... mobile phone text messages following a visit to the ... in Annals of Emergency Medicine (" A ... Patients: A Randomized Clinical Trial "). , "Each day ... to 24 visit ERs and up to half have ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Text message medicine: Texts from the ER can reduce binge drinking 2
... men who smoke had less risk of undergoing total joint ... that men who were overweight, or who engaged in vigorous ... this study are now available in Arthritis & Rheumatism ... College of Rheumatology (ACR). Research has shown that ...
... , THURSDAY, July 7 (HealthDay News) -- Suicide ... financial crisis, while road deaths decreased, according to researchers. ... percent relative increase) between 2007 and 2009. At the same ... in suicide rates seen in EU countries before 2007. ...
... belief, so-called hypoallergenic dogs do not have lower household allergen ... study by Henry Ford Hospital researchers who sought to evaluate ... home than other dogs. Hypoallergenic dogs are believed to produce ... findings are to be published online this month in the ...
... and treatment of pediatric leukemia at St. Jude Children,s Research ... M. Stratton Medal from the American Society of Hematology (ASH). ... fight against this blood cancer during the past three decades. ... of Grune and Stratton, the medical publishing house that first ...
... be reached in time to avert an unprecedented suspension of ... Medicaid and other federal health programs," Virginia Hood, MBBS, ... told the president, vice president and Congressional leaders today. ... legislation to increase the debt ceiling linked to an agreement ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, July ... dignity therapy helped terminally ill patients improve their quality ... changing how their family sees and appreciates them, according ... however, ease those distressed by dying, as the researchers ...
Cached Medicine News:Health News:Male smokers less likely to need joint replacement surgery of hip or knee 2Health News:Europe's Suicides Up, Road Deaths Down After Economy Tanked 2Health News:Study: Hypoallergenic dogs not less allergic than other dogs 2Health News:Ching-Hon Pui, M.D., honored by the American Society of Hematology for work in childhood cancer 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 3Health News:Special Talk Therapy Seems to Help Dying Patients 2Health News:Special Talk Therapy Seems to Help Dying Patients 3
... 10.1 kg, Interior Dimensions (WxDxH): 31.1 x ... (WxDxH): 44.6 x 22.4 x 20.5 cm, ... 2 - 300 x 35 mm bottles, ... or 1 - 240 x 80 mm ...
... four basic components: sample well plate, filter support ... diagram). The sample well plate is available in ... (see below). All three plates are interchangeable and ... conjunction with a complete system. The tension on ...
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
Medicine Products: